Evidence map›Paper›PMID 17308944›Full record

Trial reportPediatric cardiology

Effect of microalbuminuria lowering on regression of left ventricular hypertrophy in children and adolescents with essential hypertension.

Farahnak Assadi

2 registry-linked trialsAbstract readClinical Trial
PubMed Publisher
In one paragraph

Trial report in Pediatric cardiology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 33 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed, 2 pooled it
3.0field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03310684 completednot on this map

The Role of the Renin-Angiotensin System in Pediatric Primary Hypertension (PHRAS)

TypeobservationalSponsorWake Forest University Health SciencesRan2018 to 2023Enrolled35ConditionsPediatric Disorder, Pediatric Obesity, Primary Hypertension
NCT04752293 recruitingnot on this map

Pediatric Hypertension and the Renin-Angiotensin SystEm (PHRASE): The Role of Angiotensin-(1-7) in Hypertension and Hypertension-Induced Heart and Kidney Damage

TypeobservationalSponsorWake Forest University Health SciencesRan2021 to 2026Enrolled125ConditionsHypertension, Left Ventricular Hypertrophy, Left Ventricular Dysfunction, Left Atrial Dilatation
3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 2 syntheses or guidelines pooled it, 99 citations in OpenAlex.

  1. Pooled it
  2. Pharmacological interventions for hypertension in children.The Cochrane database of systematic reviews · 2014
    Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Antihypertensives in Children and Adolescents.Current hypertension reports · 2022
    Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Pediatric Hypertension: Parent Perspectives.Global pediatric health · 2020
    Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Review
  18. Pediatric Hypertension: Provider Perspectives.Global pediatric health · 2017
    Article
  19. Microalbuminuria in Children With Primary Hypertension.Journal of clinical hypertension (Greenwich, Conn.) · 2016
    Article
  20. Prehypertension: a warning sign of future cardiovascular risk.International journal of preventive medicine · 2014
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Farahnak AssadiRush Children's Hospital, 1725 West Harrison Street, Professional Building, Suite 710, Chicago, IL 60612, USA. fassadi@rush.edu
Rush Children's Hospital · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Microalbuminuria (MA) is associated with increased cardiovascular risk in adult hypertensive patients, but no study has specifically examined the effects of MA lowering on regression of left ventricular hypertrophy (LVH) among pediatric patients with hypertension. Fifty-five patients with essential hypertension, 11-19 years old, were prospectively studied. All patients received concomitant therapy of hydrochlorothiazide and angiotensin-converting enzyme inhibitor. Five patients also required angiotensin receptor blocker to achieve the blood pressure goal. Baseline and 12-month follow-up measures of left ventricular mass index (LVMI), determined by echocardiography and urine microalbumin/creatinine ratio (MA/Cr), were collected. MA was defined as MA/Cr >30 microg/mg. LVH was defined as LVMI >38.6 g/m(2.7). The primary end points were reductions in MA and LVMI of 25% or more. Weight (r = 0.83), body surface area (r = 0.85), body mass index (BMI) (r = 0.86), systolic blood pressure (SBP) (r = 0.57), diastolic blood pressure (DBF) (r = 0.49), mean arterial pressure (r = 0.53) and MA (r= 0.87) were all univariate correlates of LVMI. In a multiple regression analysis, MA, BMI and SBP were significant correlates of LVMI. MA alone explained 76% of the variance of LVMI, whereas BMI and SBP explained only 1.6 and 0.4% of the variance, respectively. MA was the most significant correlate of follow-up LVMI after BMI and SBP were included in the overall multiple regression models. Thus, MA is a strong predictor of LVH in hypertensive children and adolescents. MA lowering halts the progression of LVH or induces its regression.

Indexed as

AdolescentAdultAge FactorsAlbuminuriaAngiotensin-Converting Enzyme InhibitorsAntihypertensive AgentsBlood PressureChildDisease ProgressionFemaleHumansHypertensionHypertrophy, Left VentricularMaleProspective StudiesRisk FactorsAngiotensin-Converting Enzyme InhibitorsAntihypertensive Agents

Identifiers

PMID17308944
OpenAlexW2131603565

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.